title: Uveitis in Behçet disease in a tertiary center over 25 years: the KKESH Uveitis Survey Study Group.
abstract: OBJECTIVE
  To describe the features of Behçet-associated uveitis over a 25-year period.
  
  
  METHODS
  Retrospective observational case series.
  
  
  METHODS
  A chart review of patients with Behçet-associated uveitis who were evaluated from January 1986 to December 2011 at King Khaled Eye Specialist Hospital, Saudi Arabia. Demographic data, symptoms, type of uveitis, treatment, and complications were evaluated. The main outcome measures were presenting symptoms, types of uveitis, treatment, and complications.
  
  
  RESULTS
  There were 132 patients (232 eyes; 102 male [77.3%]) evaluated with age of onset of 36.9 ± 11.4 years. Panuveitis was the most common presentation, affecting 118 patients (89.4%). Episodes were bilateral in 100 patients (75.8%). Baseline best-corrected visual acuity (BCVA) was 20/125 in both eyes. Retinal vasculitis at presentation occurred in 61 eyes (26.3%), occlusive vasculitis in 59 eyes (25.4%), and macular edema in 42 eyes (18.1%). Common therapeutic management included oral corticosteroids in 123 patients (93.2%), intravenous steroid therapy in 35 patients (26.5%), cyclosporine in 98 patients (74.2%), and azathioprine in 65 patients (49.2%). Common anterior segment complications included glaucoma (44 eyes, 19%) and cataracts (34 eyes, 14.7%). The most common posterior segment complication was optic nerve atrophy. Cataract surgery was the most common surgery. At last visit, BCVA was better than 20/50 in 131 eyes (56.5%).
  
  
  CONCLUSIONS
  Behçet-associated uveitis predominantly affects young men in Saudi Arabia. Bilateral panuveitis associated with retinal vasculitis was the most common manifestation. More than 50% of patients maintained 20/50 or better BCVA at final follow-up and were primarily managed with oral corticosteroids and other immunosuppressive agents.
authors.affiliation: Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. Electronic address: arevalojf@jhmi.edu.
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.affiliation: Retina and Vitreous Service Clínica Privada de Ojos, Mar del Plata, Argentina.
authors.forename: Andres F
authors.initials: AF
authors.lastname: Lasave
authors.affiliation: Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: Mohanna Yousef
authors.initials: MY
authors.lastname: Al Jindan
authors.affiliation: Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; College of Medicine, King Khalid University, Abha, Saudi Arabia.
authors.forename: Nasser Abdulmohsen
authors.initials: NA
authors.lastname: Al Sabaani
authors.affiliation: Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: Ammar M
authors.initials: AM
authors.lastname: Al-Mahmood
authors.affiliation: Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: Yahya A
authors.initials: YA
authors.lastname: Al-Zahrani
authors.affiliation: Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
authors.forename: Hassan A
authors.initials: HA
authors.lastname: Al Dhibi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001528:Behcet Syndrome / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008269:Macular Edema / Q000209:etiology; D008297:Male; D008875:Middle Aged; D031300:Retinal Vasculitis / Q000209:etiology; D012189:Retrospective Studies; D012529:Saudi Arabia; D013256:Steroids / Q000627:therapeutic use; D014605:Uveitis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D014792:Visual Acuity
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D013256:Steroids